KRAS and lung adenocarcinoma: Although the drugs are only targeting the mutation itself, we see for example several interactions of KRAS in lung adenocarcinoma (with TP53, EGRF and STK11) and there are currently several clinical trials investigating the effectiveness and safety of targeted therapies against KRAS for this cancer type (NCT02642042, NCT01912625 or NCT02079740).